Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium. - Wikidata - wikimedia - TriplyDB

Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium.

Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium.

http://www.wikidata.org/entity/Q34743481

about

Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283.An update on dual Src/Abl inhibitors.Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis.Improving access to novel agents for childhood leukemia.How I treat childhood CML.Elucidating the identity of resistance mechanisms to prednisolone exposure in acute lymphoblastic leukemia cells through transcriptomic analysis: A computational approach.Molecular profiling of childhood cancer: Biomarkers and novel therapies Advanced targeted, cell and gene-therapy approaches for pediatric hematological malignancies: results and future perspectives A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma.Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.Pediatric chronic myeloid leukemia is a unique disease that requires a different approach Analyses of the combination of 6-MP and dasatinib in cell culture Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia A 50-year journey to cure childhood acute lymphoblastic leukemia Rapid screening of novel agents for combination therapy in sarcomas Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma.New targets and targeted drugs for the treatment of cancer: an outlook to pediatric oncology.Management of chronic myeloid leukemia in childhood.Relapsed or refractory pediatric acute lymphoblastic leukemia: current and emerging treatments.Molecular targets in the discovery and development of novel antimetastatic agents: current progress and future prospects.Xenograft and genetically engineered mouse model systems of osteosarcoma and Ewing's sarcoma: tumor models for cancer drug discovery.Drugs targeting the bone microenvironment: new therapeutic tools in Ewing's sarcoma?Therapeutic approaches to haematological malignancies in adolescents and young adults.Targeted therapies for bone sarcomas.Drugs in early clinical development for the treatment of osteosarcoma.A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials.Juvenile myelomonocytic leukaemia-associated mutation in Cbl promotes resistance to apoptosis via the Lyn-PI3K/AKT pathway.A case study of personalized therapy for osteosarcoma.Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib.Dasatinib for a child with Philadelphia chromosome-positive acute lymphoblastic leukemia and persistently elevated minimal residual disease during imatinib therapy Dasatinib inhibits proinflammatory functions of mature human neutrophils Bone sarcomas: from biology to targeted therapies.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors.Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years.Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.Acute myeloid leukemia in children: Current status and future directions.Prophylactic post-transplant dasatinib administration in a pediatric patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.

P2860

Q27025242-48967B3E-78EF-4E8D-A8D9-7666EC64492F Q28082793-8C2E904D-1C21-4B23-88DB-DA377E3EF72D Q34264571-DD216777-2F65-4B06-BDDC-6B46A5393A24 Q34270677-5E73629D-AF75-4A03-AAFD-CCFA70DB5A91 Q35224485-E103978F-5CD3-4537-A482-11C649CFA39C Q35688742-69D29603-AB61-4D5D-A376-25EC98B15272 Q35802202-CD67364D-FA37-4DCC-A1A4-C447ECA8EECA Q35856573-054CF371-BE4F-4B99-B853-B809E9891D1E Q36250783-8E5DEAD0-C667-4382-8F0E-3C57399275EB Q36804215-17B7BEEA-5CAD-495E-B6F5-D9FFD298A904 Q36888962-80F02F46-1993-4DC3-BCDD-A8D9D05F3724 Q36936139-DA1CFC9D-7AF7-4946-838D-F00B61F79746 Q37025981-A9449978-A58D-41DB-88E1-18B0B87F5427 Q37091715-FBCC1C62-3BEB-4253-B179-80EBBD7E5241 Q37150014-0E1610D4-1B9C-4C47-9277-60FF93D99090 Q37166753-90DB60A5-15EE-4E85-98EC-A83FAD24E9CB Q37298877-DB912659-B224-42DA-9719-F467F56B09DA Q37662300-DA23D79A-529B-4845-93B8-40E6476CB0F3 Q37936432-D71F82FB-8B5D-4C0F-B693-E8EFCB30115B Q37991223-2656A535-64AA-4954-8DD0-514291BB1FCC Q38033592-9B4F7CD0-2E24-4262-A314-191ED47599CF Q38093654-528F24D8-E8FD-4C46-9676-AD0DB0F416AA Q38120777-6F39C3F5-060C-488C-9E17-D925DBA45594 Q38129954-0134E3F6-2CB1-419C-911B-409E4A7D74A5 Q38134399-6992E0E0-1012-47B1-99DE-387929EC93FC Q38178277-2FBD5F97-5AB5-4581-8F95-32ADBFF1A85B Q38955517-6EC33191-4955-43FB-A88F-8B5DE351EBAA Q38961012-1C6CE4D3-D28F-4F15-ABA3-E971CD85C813 Q39029990-D4238F2C-233A-4D1B-81E1-FE61FB5A0D30 Q39176157-36BEBB08-10C5-43B9-9208-502D5978F034 Q41763725-BEB1211E-7108-4C79-B19B-E56318C40CFA Q41863632-7502CE08-FB7D-47DD-9E29-9D7D00F718DD Q41885572-DD4831A4-66C6-4C29-840C-CD55FDB575F1 Q41923624-B254B981-D146-45A3-9432-67AB81D7F8BE Q43841175-B19421DD-630A-40E8-AB68-F923BF528EEB Q48503168-13C50D51-C55F-401F-BC75-35F5FA020117 Q51072279-D40DC6B9-68AE-4E22-AA42-C4E98217EFBC Q52677126-F7ED4631-3B3A-4B98-A2CB-0BD51DF12AC4 Q52897332-084A839D-7C15-4685-BCE6-0945EC693CB7 Q54424684-09091CB4-CF56-4C75-A1BC-B17B12B65719

P2860

Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium.

http://www.wikidata.org/entity/Q34743481

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Pediatric phase I trial and ph ...... logy group phase I consortium.

@ast

Pediatric phase I trial and ph ...... logy group phase I consortium.

@en

Pediatric phase I trial and ph ...... logy group phase I consortium.

@nl

type

label

Pediatric phase I trial and ph ...... logy group phase I consortium.

@ast

Pediatric phase I trial and ph ...... logy group phase I consortium.

@en

Pediatric phase I trial and ph ...... logy group phase I consortium.

@nl

prefLabel

Pediatric phase I trial and ph ...... logy group phase I consortium.

@ast

Pediatric phase I trial and ph ...... logy group phase I consortium.

@en

Pediatric phase I trial and ph ...... logy group phase I consortium.

@nl

P1433

Q34743481-679F64BC-08C9-434C-A1A7-ABE537120D0E

P1476

Q34743481-772E276B-12BA-434F-A4E8-B306FF3BAB3D

P2093

Q34743481-053D71A8-6A6C-43CB-A81D-D28609BFC10D

Q34743481-54721B5C-E697-4063-9CDE-8F2B4BAB3F58

Q34743481-61B414FC-4528-4D6D-A8F8-72A54593B4FC

Q34743481-6821466A-EBCA-4AB4-9C51-B5F4C8B37E59

Q34743481-7C7F1427-93BE-48E9-803E-FD7D3CB2F42B

Q34743481-85BCC6AF-8D92-4AC2-9168-F7435CBA4A31

Q34743481-B31A0766-09CB-4961-9C07-102928CD33E1

Q34743481-DB83780B-7F63-45A6-BA44-2B7A25D9B3E8

P2860

Q34743481-2221E237-BBF9-4378-A4F5-FD71E33C9251

Q34743481-2C46CD36-DA08-46D0-BFF8-79850AC52680

Q34743481-30B5859F-94ED-491D-8294-634922F7286D

Q34743481-357EE9FB-E943-4CF8-B5A7-D1A78927ABA1

Q34743481-4861BC26-786C-460B-B058-C9149C7A36E4

Q34743481-5BD68FDF-C842-4F0A-B238-C3D8A5C16409

Q34743481-656D29F0-44FC-4661-8762-888EBBED069B

Q34743481-8BFDBC14-A247-42FA-AB65-45184B8F88F9

Q34743481-BDC3368D-8E03-413B-8B9E-0B899C1A1EA7

Q34743481-D0AFC090-C0F2-4454-AE5F-44F9E7BC0208

P304

Q34743481-3E6E34A1-9555-4B10-9589-1EE449F21CD8

P31

Q34743481-CB918786-1A21-4A93-A6B7-A5B9F701340F

P356

Q34743481-FF5F5B03-7A31-4019-8E41-B0BBF8782BE2

P407

Q34743481-B6270BCA-8653-4091-83AC-0B1CD44E2FBD

P433

Q34743481-78DFEACC-942F-45F8-857E-EB05352BE6C9

P478

Q34743481-8EE142DC-E76D-45B7-8863-B9AD40E97305

P50

Q34743481-128ECF42-1F7E-4835-AA66-339104D7AFEA

Q34743481-289C3F50-77E4-4DD9-B36D-0A4544B9E2A0

P577

Q34743481-A1FD8A58-0763-43A5-A11E-B3A8AE98D9BF

P698

Q34743481-7C8A2044-040E-4873-A1E4-F1140A57AF31

P921

Q34743481-673AA5BA-ED2F-42EA-8864-80409AA00C3D

P932

Q34743481-D58176E5-1FB5-4E56-8FCD-EF7AA4A06BAF

P356

JCO.2010.30.7231

P1433

Journal of Clinical Oncology

P1476

Pediatric phase I trial and ph ...... logy group phase I consortium.

@en

P2093

Ashish Mark Ingle

http://www.w3.org/2001/XMLSchema#string

John J Wright

http://www.w3.org/2001/XMLSchema#string

Junfeng Sun

http://www.w3.org/2001/XMLSchema#string

Lewis C Strauss

http://www.w3.org/2001/XMLSchema#string

Peter C Adamson

http://www.w3.org/2001/XMLSchema#string

Richard Aplenc

http://www.w3.org/2001/XMLSchema#string

Shruti Agrawal

http://www.w3.org/2001/XMLSchema#string

Suzanne Shusterman

http://www.w3.org/2001/XMLSchema#string

P2860

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Overriding imatinib resistance with a novel ABL kinase inhibitor

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.

Measures of response: RECIST, WHO, and new alternatives.

Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.

Initial testing of dasatinib by the pediatric preclinical testing program.

Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.

Metabolism and disposition of dasatinib after oral administration to humans.

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?

P304

839-844

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2010.30.7231

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-01-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21263099

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

3068059

http://www.w3.org/2001/XMLSchema#string